written on 25.06.2014

Reuters: Valeant supporter Paulson grabs 6 million-plus Allergan shares


Tuesday, Valeant CEO J. Michael Pearson said his company was close to luring the 25% of Allergan investors it needs to call a special meeting, where it believes it can shake up Allergan's board and dismantle its poison pill defense to make way for a takeover. And now, the Canadian pharma may have just picked up some more support.